The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
|Articles|September 22, 2016
Does Surveillance With CA-125 in Ovarian Cancer Benefit Patients?
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that found that surveillance with CA-125 in ovarian cancer patients led to more use of chemotherapy, decreased quality of life, and no improvement in survival.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5